Surplus vitamin B12 use does not reduce fatigue in patients with Irritable Bowel Syndrome or inflammatory bowel disease: A randomized double-blind placebo-controlled trial.

What Was Tested

This randomized controlled trial looks at Cyanocobalamin (Vitamin B12).

The researchers performed a randomized placebo controlled trial to investigate the effect of surplus oral vitamin B12 supplementation on fatigue in patients with IBS or IBD.

Who Took Part

By PubMed's age tags, the people studied were teenagers, young adults, adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Because people in this Cyanocobalamin (Vitamin B12) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Cyanocobalamin (Vitamin B12).

The comparison arm used a placebo, so changes seen with Cyanocobalamin (Vitamin B12) could be set against what happens without it.

The primary outcome measure was fatigue (Checklist Individual Strength (CIS)).

In addition, measures of quality of life and depression were examined.

What Was Measured

The subject headings attached to it are Biomarkers, Dietary Supplements, Fatigue, Inflammatory Bowel Diseases, Irritable Bowel Syndrome, Quality of Life and Surveys and Questionnaires.

The authors tagged it with the keywords IBD, IBS and Vitamin B(12) supplementation.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Cyanocobalamin (Vitamin B12).

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2018 (Clinical nutrition ESPEN), a journal based in England.

More context: the Cyanocobalamin (Vitamin B12) compound page, all human trials.